-
Novel Approaches Under Investigation
-
9278 Shared Decistion Making IRL
-
A Factor VIII Variant With Elimination of the N-glycosylation Site at 2118 Reduced Anti-FVIII Immune Responses in Gene Therapy Treated Hemophilia A Mice
-
A New Tool to Assist in Treatment Selection–The World Federation of Hemophilia (WFH) Shared Decision-making (SDM) Tool
-
AAV Integration Analysis After Long Term Follow-up in Hemophilia A Dogs Reveals the Genetic Consequences of AAV-Mediated Gene Correction
-
Adeno-Associated Viral (AAV) Vector Gene Therapy: Application to Hemophilia
-
Breaking Transgene Tolerance via Immunosuppression
-
Characterisation of Adeno-Associated Virus Vector Persistence After Long-Term Follow-up in the Haemophilia A Dog Model
-
Delivery of CRISPR/Cas9 mRNA LNPs to Repair a Small Deletion in FVIII Gene in Hemophilia A Mice
-
Development of adeno-associated virus (AAV5) variants capable of reducing the immunogenicity by targeting antigenic residues on the capsid surface
-
Development of Coagulation Factor VIII Transgenes That Confer Greater Potency to Gene Therapies for Hemophilia A Through Ancestral Sequence Reconstruction
-
Evolution Directed Gene Engineered (EDGE) Gain-of-Function Factor VIII Variants Enhance Gene Therapy for Hemophilia A
-
Expert of the Month Interviews: March
-
Frequency, Location and Nature of AAV Vector Insertions After Long-term Follow-up of FVIII Transgene Delivery in a Hemophilia A Dog Model
-
Frequent Updates from the Field
-
Gene Therapy for FVIII
-
Highlights from the NHF 15th Workshop on Novel Technologies and Gene Transfer for Hemophilia
-
Improved hFIX and hFVIII expression with ITR-modified AAV vectors in hemophilic mice
-
Key Considerations: Advances in Gene Therapy for Hemophilia
-
Key Considerations: Advances in Gene Therapy for Hemophilia ENDURING